A bottle of minoxidil solution beside a dropper on a bathroom counter
Minoxidil is a prodrug — it does nothing until a scalp enzyme converts it into minoxidil sulfate. How much of that enzyme you have in your hair follicles varies enormously from person to person, and it is the single best predictor of whether the drug will work for you.

Minoxidil is the most widely used hair-loss treatment in the world, and for most people it works: across the pivotal trials, roughly 60–80% of users show measurable regrowth. But that statistic has a flip side that marketing rarely mentions — somewhere between one in five and two in five people see nothing at all, no matter how diligently they apply it. Our review of minoxidil for female pattern hair loss noted this 20–40% non-responder rate; this article explains why it happens.

The dominant reason is not adherence, dosing, or bad luck. It is a specific enzyme in the hair follicle — and whether your scalp makes enough of it to turn minoxidil into the form that actually grows hair.

The Claim

“Clinically proven to regrow hair. Just apply twice daily and see thicker, fuller hair in as little as three to six months.”

(Composite representative claim reflecting Rogaine and generic minoxidil marketing.)

The Prodrug Problem: Minoxidil Is Inactive Until Your Scalp Changes It

Here is the fact that reframes everything: minoxidil itself does not grow hair. It is a prodrug — an inactive precursor that the body has to chemically convert into the molecule that does the work. That active molecule is minoxidil sulfate, and the conversion is carried out by a family of enzymes called sulfotransferases, with SULT1A1 in the hair follicle doing most of the job. Laboratory work has confirmed that several human sulfotransferases contribute to minoxidil sulfation, but the follicular enzyme is the one that matters for topical treatment.

So the drug you apply to your scalp is a key that does not fit the lock until a local enzyme reshapes it. If your follicles express plenty of SULT1A1, a good fraction of the minoxidil you apply becomes active minoxidil sulfate and you are likely to respond. If your follicles express little of it, most of the drug sits there unconverted — and you can apply it perfectly, twice a day, for a year, and see almost nothing. The problem is not the application. It is the chemistry downstream of it.

The Enzyme Predicts Response — With Striking Accuracy

This is not a hypothesis. Enzyme activity in plucked hair follicles has been measured directly and tested against real-world response. In a study developing an enzymatic assay to predict minoxidil response, researchers found that follicular SULT1A1 activity correlated with who regrew hair. A follow-up study in women with androgenetic alopecia found that sulfotransferase activity in plucked hair follicles predicted response with about 93% sensitivity and 83% specificity — numbers that rival many diagnostic tests used in routine medicine.

Why does the enzyme vary so much between people? A study of 120 subjects measuring follicular sulfotransferase before and after treatment found the expression of the enzyme in the scalp varies greatly between individuals, and that this difference explains the varied response to minoxidil. Genetics, other medications competing for the same enzyme, and even the enzyme's own regulation all play a role. The practical upshot is that response is, to a large degree, determined before you ever open the bottle. This is why researchers increasingly describe follicular SULT1A1 activity as a prognostic marker for minoxidil treatment.

Can You Raise Your Enzyme Activity?

If low enzyme activity is the bottleneck, the obvious question is whether it can be boosted. Two lines of evidence suggest it can — with appropriate caution about study size. First, tretinoin has been shown to enhance minoxidil response by upregulating follicular sulfotransferase, which is part of the rationale behind combination minoxidil-plus-tretinoin formulations. Second, a study of a SULT1A1 enzyme “booster” adjuvant reported that 75% of subjects who used the booster with daily minoxidil for 60 days regrew hair, versus 33% using a placebo adjuvant.

These are promising but small, single-center findings, and the booster products marketed on the back of them run well ahead of the evidence. The honest read is that the enzyme is a plausible, partially modifiable target — not a solved problem you can reliably buy your way around.

The Other Reasons Minoxidil Appears to “Fail”

The enzyme is the headline, but several non-biological reasons make minoxidil look like it failed when it never got a fair trial:

Quitting too early. Minoxidil needs roughly 4–6 months of consistent twice-daily use before results are visible, and maximal response takes longer. People who judge it at 8 weeks are judging it before it has had a chance to work.

The initial shedding phase. Minoxidil synchronizes follicles into the growth phase, which causes a temporary burst of shedding in the first 2–8 weeks. This is a sign the follicles are responding, but it looks like the drug is making things worse, and it drives people to stop right before the benefit arrives.

The wrong diagnosis. Minoxidil's evidence base is for androgenetic alopecia. If the real cause is something else — such as telogen effluvium, a thyroid issue, or iron deficiency — minoxidil is treating the wrong problem, and no amount of enzyme will help.

Maintenance-dependence mistaken for failure. Minoxidil does not cure the underlying process; it holds it back. Regrowth reverses within 3–6 months of stopping. People who pause and watch the gains disappear sometimes conclude “it stopped working,” when in fact it was working exactly as expected and was withdrawn.

What the Evidence Actually Shows

The “clinically proven” claim is true — for the majority. But it hides a real biological lottery. Because minoxidil is a prodrug that the follicular enzyme SULT1A1 must convert into active minoxidil sulfate, people with low follicular enzyme activity convert too little of it to matter, and are true non-responders. Enzyme activity in plucked follicles predicts response with roughly 93% sensitivity and 83% specificity, and expression varies widely between individuals. On top of this biological ceiling sit avoidable failures: quitting during the early shedding phase, not waiting the required 4–6 months, misdiagnosis, and mistaking maintenance-dependence for loss of efficacy.

Verdict & Practical Implications

Verdict: Partially Supported

The “clinically proven” claim is well-supported for the majority — but it is only partially true as a blanket promise, because 20–40% of people are genuine non-responders. The reason is well-established science, not marketing spin: minoxidil is an inactive prodrug that the follicular enzyme SULT1A1 must convert into active minoxidil sulfate, and that enzyme's activity varies enormously between people and is a validated predictor of response. Evidence rating: 4/5 — the mechanism is consistent and replicated; what marketing omits is that a substantial minority cannot respond regardless of effort.

What does this mean if minoxidil hasn't worked for you? First, make sure you actually gave it a fair trial — correct diagnosis, twice daily, at least 4–6 months, through the shedding phase. If you did all that and saw nothing, you may genuinely be a low-enzyme non-responder, and the productive moves are different: a tretinoin combination to upregulate the enzyme, a switch to oral minoxidil, which is processed differently and can help some topical non-responders, or an evidence-backed alternative such as a DHT blocker. A sulfotransferase assay to predict response exists in the research literature but is not yet a routine clinical test — so for now, a carefully monitored trial of these alternatives is the practical substitute.

References & Further Reading